JP Morgan Chase
MIRM icon

JP Morgan Chase’s Mirum Pharmaceuticals MIRM Stock Holding History

JP Morgan Chase’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
81,001
-9,663
-11% -$970K ﹤0.01% 2777
2026
Q1 		$7.97M Sell
90,664
-6,722
-7% -$632K ﹤0.01% 2887
2025
Q4 		$7.69M Sell
97,386
-2,823
-3% -$203K ﹤0.01% 2939
2025
Q3 		$7.35M Sell
100,209
-380,067
-79% -$24.2M ﹤0.01% 3005
2025
Q2 		$24.4M Buy
480,276
+192,340
+67% +$8.56M ﹤0.01% 1806
2025
Q1 		$13M Sell
287,936
-97,206
-25% -$4.58M ﹤0.01% 2313
2024
Q4 		$15.9M Buy
385,142
+357,381
+1,287% +$14.9M ﹤0.01% 2245
2024
Q3 		$1.08M Buy
27,761
+3,929
+16% +$157K ﹤0.01% 4420
2024
Q2 		$815K Sell
23,832
-121,728
-84% -$3.19M ﹤0.01% 4400
2024
Q1 		$3.66M Sell
145,560
-41,023
-22% -$1.13M ﹤0.01% 3360
2023
Q4 		$5.51M Buy
186,583
+86,807
+87% +$2.63M ﹤0.01% 2990
2023
Q3 		$3.15M Buy
99,776
+61,311
+159% +$1.68M ﹤0.01% 3189
2023
Q2 		$995K Buy
38,465
+24,262
+171% +$645K ﹤0.01% 4069
2023
Q1 		$341K Sell
14,203
-64,368
-82% -$1.47M ﹤0.01% 4728
2022
Q4 		$1.53M Buy
78,571
+64,388
+454% +$1.27M ﹤0.01% 3760
2022
Q3 		$299K Buy
14,183
+4,048
+40% +$97.5K ﹤0.01% 4754
2022
Q2 		$197K Buy
10,135
+4,816
+91% +$114K ﹤0.01% 5088
2022
Q1 		$117K Sell
5,319
-17,250
-76% -$352K ﹤0.01% 5429
2021
Q4 		$360K Buy
22,569
+2,573
+13% +$40K ﹤0.01% 5022
2021
Q3 		$399K Sell
19,996
-20,001
-50% -$325K ﹤0.01% 4856
2021
Q2 		$691K Buy
39,997
+23,892
+148% +$428K ﹤0.01% 4512
2021
Q1 		$319K Buy
16,105
+13,774
+591% +$264K ﹤0.01% 4937
2020
Q4 		$41K Sell
2,331
-5,149
-69% -$101K ﹤0.01% 5201
2020
Q3 		$145K Buy
7,480
+2,856
+62% +$61.3K ﹤0.01% 4524
2020
Q2 		$90K Sell
4,624
-3,640
-44% -$60.8K ﹤0.01% 4615
2020
Q1 		$116K Buy
8,264
+3,987
+93% +$65.4K ﹤0.01% 4473
2019
Q4 		$105K Buy
4,277
+3,352
+362% +$35.7K ﹤0.01% 4875
2019
Q3 		$9K Buy
+925
New +$11.3K ﹤0.01% 5517

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's MIRM Position: Q2 2026 in Review

JP Morgan Chase reduced its Mirum Pharmaceuticals (MIRM) stake by 11% in Q2 2026, selling an estimated $970K and leaving 81,001 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2777.

JP Morgan Chase first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. The position peaked at $24.4M in Q2 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • JP Morgan Chase held 81,001 shares of Mirum Pharmaceuticals worth $10.2M as of Q2 2026.
  • JP Morgan Chase sold 9,663 Mirum Pharmaceuticals shares in Q2 2026, an estimated $970K.
  • Mirum Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2777 holding.
  • JP Morgan Chase first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Mirum Pharmaceuticals position peaked at $24.4M in Q2 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.